Overview

This trial is active, not recruiting.

Conditions rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus (sle), dermatomyositis (dm), dmixed connective tissue disease, systemic vasculitis, systemic sclerosis (ssc), sjögren's syndrome, antiphospholipid syndrome, juvenile idiopathic arthritis, juvenile sle, juvenile dm
Treatment anti-pandemic h1n1 influenza vaccine
Phase phase 4
Sponsor University of Sao Paulo
Collaborator Fundação de Amparo à Pesquisa do Estado de São Paulo
Start date April 2010
End date July 2010
Trial size 5000 participants
Trial identifier NCT01151644, CEDMAC-H1N1

Summary

The prognosis of rheumatic diseases has improved considerably with development of therapy. However, infections are considered the most important cause of morbidity and mortality in this group of patients. One of the ways to prevent such complications is vaccination. In 2009, a new pandemic strain of influenza virus (A/H1N1/2009) has emerged raising major concerns for public health. Patients under immunosuppressive therapy have indication for immunization against influenza virus H1N1. There are, however, concerns about possibility of reactivation of autoimmune diseases, determine adverse events and insufficient immunogenicity in these patients. The lack of studies evaluating the efficacy and safety of the vaccine against influenza A(H1N1)/2009 in these rheumatic patients led to the development of this research. The objectives of this study are to evaluate the humoral response and safety of the vaccine virus A(H1N1)/2009 in immunosuppressed patients with rheumatic diseases compared to healthy controls. We have recruited 400 patients with rheumatoid arthritis, 350 with spondyloarthritis, 1000 with systemic lupus erythematosus (SLE), 150 with dermatomyositis (DM), 100 with mixed connective tissue disease, 150 with systemic vasculitis, 250 with systemic sclerosis (SSc) , 100 with Sjögren's syndrome, 100 with antiphospholipid syndrome, 100 patients with juvenile idiopathic arthritis, 80 with juvenile SLE, and 80 with juvenile DM, followed at our Rheumatology Outpatient Division and Unit Pediatric Rheumatology Children's Institute, HC-FMUSP. The control group was recruited were 200 healthy employees of ICHC-FMUSP. Informed consent was obtained from all participants and the study was approved by the Local Ethical Committee. All subjects were vaccinated against influenza virus A/(H1N1)/2009 (vaccine approved and supplied by Instituto Butantan-São Paulo). Blood samples was collected to measure levels of antibodies inhibiting hemagglutination by influenza virus A (H1N1)/2009 immediately prior to vaccination and 21 to 28 days after vaccination., Participants fulfilled a questionnaire on the immediate side effects of the vaccine. All patients with rheumatoid arthritis, spondyloarthritis, SLE, DM, systemic vasculitis, juvenile idiopathic arthritis, juvenile SLE, and DM were assessed before and 21 days after vaccination for clinical, laboratory parameters of disease activity as well as treatment. Continuous variables will be compared by t-test to evaluate differences between patients with rheumatic diseases versus healthy controls. Differences between categorical variables will be evaluated using the chi-square or Fisher exact test. Statistical significance was set at p<0.05.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose prevention
Arm
(Active Comparator)
anti-pandemic h1n1 influenza vaccine
inactivated, NON-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
(Active Comparator)
anti-pandemic h1n1 influenza vaccine
inactivated, NON-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)

Primary Outcomes

Measure
Safety (adverse effects) and efficacy (serconversion rate) after 21 days from the vaccination
time frame: Before and after 21 days from vaccination

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Rheumatic diseases according to international criteria of each disorder Exclusion Criteria: - Previous and confirmed infection by virus A(H1N1)/2009 - History of anaphylatic reaction to egg components - Acute fever - Guillain-Barré syndrome, heart failure (classes III or IV), demyelinating disease

Additional Information

Official title Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases
Trial information was received from ClinicalTrials.gov and was last updated in June 2010.
Information provided to ClinicalTrials.gov by University of Sao Paulo.